Prevention and treatment of proteinuria in diabetic nephropathy

Comparing administrating ARBs Vs ARB plus N-acetyl cysteine on reducing proteinuria in the patients suffering from type-II diabetes mellitus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104046123N1

Enrollment

Registered

2011-04-19

Start date

2011-03-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy. Glomerular disorder in diabetes mellitus

Interventions

Intervention 1: Intervention group: N-acetylcyctein 600mg twice daily as well as Losartan 25mg twice daily for two months. Intervention 2: In control group: Losartan 25 mg twice in day for two month.

Treatment - Drugs

Intervention group: N-acetylcyctein 600mg twice daily as well as Losartan 25mg twice daily for two months

In control group: Losartan 25 mg twice in day for two month.

Eligibility

Sex/Gender

All

Age

25 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: willing to participate, no underlying malignancy, creatinin more than 1.8 Exclusion criteria: no any other diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Proteinuria. Timepoint: before intervention and two monthS after treatment. Method of measurement: Urine collection in 24 hrs.	—

Secondary

Measure	Time frame
Hemoglobin A1C. Timepoint: Before intervention and two months after treatment. Method of measurement: taking blood sample.;Blood suger. Timepoint: Before intervention and two months after treatment. Method of measurement: take blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sadreddin Rasi Hashemi

Tabriz University of Medical Sciences

rasihashemis@tbzmed.ac.ir+98 41 1334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026